Document Detail

PET/CT and renal pathology: a blind spot for radiologists? Part 1, primary pathology.
MedLine Citation:
PMID:  22826417     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: PET/CT with (18)F-FDG shows metabolically active disease and is widely used for the diagnosis and follow-up of patients with cancer. Nonmetabolically active renal pathology may be missed without close attention to the CT portion of the study, whereas metabolically active pathology may be missed on PET because of physiologic tracer excretion in the kidneys. This article illustrates primary lesions of the kidney on FDG PET/CT with emphasis on key anatomic features and the appearance of tracer uptake.
CONCLUSION: Close attention to both the FDG PET and CT portions of the study is essential to interpret renal pathology correctly on FDG PET/CT examinations.
Katherine Zukotynski; Aaron Lewis; Kevin O'Regan; Heather Jacene; Christopher Sakellis; Katherine Krajewski; David Israel
Related Documents :
17594277 - Use of virtual reality distraction to reduce claustrophobia symptoms during a mock magn...
24771357 - Optimization of scanning parameters for mr elastography at 3.0 t clinical unit: volunt...
22955797 - Automated estimation of abdominal effective diameter for body size normalization of ct ...
21125477 - Neuroimaging research on cerebrovascular spasm and its current progress.
8772657 - Quantification of serial tumor glucose metabolism.
15185757 - Spontaneous regression of a primary cerebral tumor following vasospasm caused by subara...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  AJR. American journal of roentgenology     Volume:  199     ISSN:  1546-3141     ISO Abbreviation:  AJR Am J Roentgenol     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-24     Completed Date:  2012-10-24     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  7708173     Medline TA:  AJR Am J Roentgenol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  W163-7     Citation Subset:  AIM; IM    
Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Diagnosis, Differential
Fluorodeoxyglucose F18 / diagnostic use
Kidney Neoplasms / pathology,  radionuclide imaging*
Positron-Emission Tomography and Computed Tomography*
Radiopharmaceuticals / diagnostic use
Reg. No./Substance:
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Preoperative needle biopsy of sentinel lymph nodes using intradermal microbubbles and contrast-enhan...
Next Document:  PET/CT and renal pathology: a blind spot for radiologists? Part 2--lymphoma, leukemia, and metastati...